Skip Navigation



Journal of the National Cancer Institute Advance Access published online on September 25, 2007
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djm135
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow JNCI Podcast
Right arrow All Versions of this Article:
99/19/1441    most recent
djm135v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Trédan, O.
Right arrow Articles by Tannock, I. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trédan, O.
Right arrow Articles by Tannock, I. F.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

REVIEW

Drug Resistance and the Solid Tumor Microenvironment

Olivier Trédan, Carlos M. Galmarini, Krupa Patel, Ian F. Tannock

Affiliations of authors: Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada (OT, KP, IFT); Université Claude Bernard Lyon 1, ENS-CNRS UMR 5239, Oullins, France (CMG)

Correspondence to: Ian F. Tannock, MD, PhD, Princess Margaret Hospital, Ste 5-208, 610 University Ave, Toronto, ON M5G 2M9, Canada (e-mail: ian.tannock{at}uhn.on.ca).

Resistance of human tumors to anticancer drugs is most often ascribed to gene mutations, gene amplification, or epigenetic changes that influence the uptake, metabolism, or export of drugs from single cells. Another important yet little-appreciated cause of anticancer drug resistance is the limited ability of drugs to penetrate tumor tissue and to reach all of the tumor cells in a potentially lethal concentration. To reach all viable cells in the tumor, anticancer drugs must be delivered efficiently through the tumor vasculature, cross the vessel wall, and traverse the tumor tissue. In addition, heterogeneity within the tumor microenvironment leads to marked gradients in the rate of cell proliferation and to regions of hypoxia and acidity, all of which can influence the sensitivity of the tumor cells to drug treatment. In this review, we describe how the tumor microenvironment may be involved in the resistance of solid tumors to chemotherapy and discuss potential strategies to improve the effectiveness of drug treatment by modifying factors relating to the tumor microenvironment.

Manuscript received February 16, 2007; revised July 12, 2007; accepted August 3, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 1421. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
S. L. Gonias
Urokinase: the identity crisis continues
Blood, July 1, 2008; 112(1): 8 - 8.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.